...Philipp le Coutre; Andreas Burchert; Susanne Saußele; Thekla Schwarzer; Sebastian Stintzing; Uwe Pelzer; Lars Bullinger; Ahmet Elmaagacli; Christian Jehn; Frank Stegelmann; Andreas Hochhaus; Thomas Ernst; Joachim R. Göthert Introduction: In chronic myeloid leukemia patients, second-line treatment...

... of life (HRQoL) in patients with chronic myeloid leukemia (CML). Methods: Medical records of 345 patients with CML treated with at least one type of TKI were retrospectively reviewed. Results: No significant differences in survival were observed based on the number of different TKIs the patients received...

...Qiushi Liang; Zhigang Liu; Yu Wu; Huanling Zhu; Yunfan Yang Introduction: Treatment-free remission (TFR) has emerged as a new goal in the treatment of chronic myeloid leukemia (CML). TFR is considered a safe intervention because patients who experienced molecular relapse usually responded well...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Adverse events Bosutinib Chronic myeloid leukemia Tyrosine kinase inhibitors Tyrosine kinase inhibitors (TKIs) ensure that most patients with chronic myeloid leukemia...

...Patrice E. Nasnas; Elias J. Jabbour; Koji Sasaki; Ghayas C. Issa; Lucia Masarova; Nicholas J. Short; Fadi G. Haddad Introduction: Treatment discontinuation and treatment-free remission (TFR) emerged as the new goal of therapy in patients with chronic myeloid leukemia in chronic phase (CML-CP...

.... 2023 Chronic myeloid leukemia Ponatinib Dosing regimens Cardiovascular management Consensus paper According to the ELN recommendations 2020, the third-generation tyrosine kinase inhibitor (3G TKI) ponatinib is currently the most potent TKI used in CML [ 1 ]. Ponatinib is effective...

... to in the content or advertisements. 2023 T-cell blast crisis Chronic myeloid leukemia Allogeneic bone marrow transplantation The Philadelphia chromosome (t(9; 22) (q34; q11)) is the hallmark of chronic myelogenous leukemia (CML) but is also present in 15–30% of adult B-cell acute lymphoblastic...

...Ali McBride; John Brokars; Sheila Reiss Reddy; Eunice Chang; Marian H. Tarbox; Thomas W. LeBlanc Introduction: Treatment with dasatinib for chronic myeloid leukemia (CML) has been associated with development of pleural effusion; however, data regarding its optimal management are limited. We...

... to treatment. Methods: We evaluated the IRF4 expression kinetics during tyrosine kinase inhibitor (TKI) treatment in a cohort of 116 chronic myeloid leukemia (CML) patients to elucidate its role in the disease course. Results: A relationship between the IRF4 expression and the disease burden was observed...

...Tamar Berger; Adi Shacham Abulafia; Shai Shimony; Oren Pasvolsky; Iuliana Vaxman; Yifat Miron; Shimrit Feldman; Avi Leader; Pia Raanani Introduction: Data regarding the prevalence of paraproteinemia in patients with chronic myeloid leukemia (CML) are lacking. Methods: To evaluate for the prevalence...

...Jolanta Dengler; Hans Tesch; Kathleen Jentsch-Ullrich; Anke Gerhardt; Clemens Schulte; Jörg Lipke; Gunnar Löwe; Alexander Kiani Introduction: Treatment-free remission (TFR) is increasingly considered as treatment goal for patients with chronic myeloid leukemia (CML), but information...

...An Quoc To; Stefan O. Ciurea; Piyanuch Kongtim Bleeding complications in patients with myeloproliferative neoplasms are known to be related to acquired von Willebrand disease or platelet dysfunction. Here, we describe two very similar cases of chronic phase chronic myeloid leukemia with extreme...

... and report on their environmental exposures that may have contributed to CML pathogenesis. The possible familial association of these 2 cases of CML warrants further investigation into more definitive etiologies of this disease. Chronic myeloid leukemia Hereditary cancer syndromes Familial cancer...

... Background: Philadelphia chromosome-positive (Ph+) advanced leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in myeloid blast phase (MBP), have poor outcomes. Venetoclax has shown synergism with BCR-ABL1 tyrosine kinase inhibitors (TKI) in preclinical studies. However...

... Treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia (Ph+ ALL) has been revolutionized with the advent of tyrosine kinase inhibitors (TKIs). Most patients with CML achieve long-term survival similar to individuals without CML due to treatment with TKIs not only...

... (NG-TKIs; including dasatinib, nilotinib, bosutinib, radotinib, and ponatinib) versus imatinib for patients with newly diagnosed chronic myeloid leukemia (CML). Summary: We identified randomized controlled trials comparing the efficacy of NG-TKIs versus imatinib as the first-line treatment for CML...

...; Andrea Biondi; Franco Locatelli; Robin Foà Background: To date, no data on the adherence to specific guidelines for children with chronic myeloid leukemia (CML) in chronic phase (CP) have been reported. Methods: Since 2001, guidelines for treatment with imatinib mesylate (IM) and monitoring in patients...

... stimulated CD3+ cells from 38 chronic myeloid leukemia (CML) patients. At the time of diagnosis the percentages of cells producing INF-γ, TNF-α, and IL-2 were strongly suppressed compared to those in healthy control subjects. Hematological remission achieved through treatment with tyrosine-kinase inhibitors...

... as weighted mean of RDD, were 0.35 ± 0.10 g in year 1 and 0.35 ± 0.08 g in year 2, and mean PDD values are 0.38 ± 0.07 and 0.37 ± 0.06 g, respectively. Table 4 Outcome with respect to adherence cutoffs Chronic myeloid leukemia (CML) is a clonal disease of hematopoietic stem cells...

...Guili Zhang; Fei Dong; Caifu Luan; Xia Zhang; Huiyuan Shao; Jie Liu; Chengming Sun We aimed to investigate the role of CCAAT enhancer-binding protein α (C/EBPα) in the pathogenesis of chronic myeloid leukemia (CML) and the mechanism underlying its effect. Bone marrow specimens from 50 patients...